Patent: 11,045,540
✉ Email this page to a colleague
Summary for Patent: 11,045,540
| Title: | Varicella zoster virus (VZV) vaccine |
| Abstract: | Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described. |
| Inventor(s): | Giuseppe Ciaramella |
| Assignee: | ModernaTx Inc |
| Application Number: | US16/494,162 |
| Patent Claims: | see list of patent claims |
Details for Patent 11,045,540
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Llc | PROQUAD | measles, mumps, rubella and varicella virus vaccine live | For Injection | 125108 | September 06, 2005 | 11,045,540 | 2038-03-15 |
| Merck Sharp & Dohme Llc | PROQUAD | measles, mumps, rubella and varicella virus vaccine live | For Injection | 125108 | February 27, 2023 | 11,045,540 | 2038-03-15 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 11,045,540
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2018170270 | ⤷ Start Trial |
| United States of America | 2025041407 | ⤷ Start Trial |
| United States of America | 2022409720 | ⤷ Start Trial |
| United States of America | 2020069793 | ⤷ Start Trial |
| United States of America | 12622960 | ⤷ Start Trial |
| United States of America | 11918644 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
